Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|173|4|1015-1023

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.173, Iss.4, 2015-10, pp. : 1015-1023

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessment of diagnostic criteria between primary cutaneous anaplastic large‐cell lymphoma and CD30‐rich transformed mycosis fungoides; a study of 66 cases

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 6, 2015-06 ,pp. : 1547-1554

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large‐cell lymphoma: what is the cost?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1474-1475

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pyoderma gangrenosum‐like CD30+  cutaneous T‐cell lymphoma in a patient with mycosis fungoides

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 4, 2015-04 ,pp. : 819-821

John Wiley & Sons Inc

Access to resources Recommend Favorite

Primary cutaneous T‐cell lymphoma presenting as mycosis fungoides with a T‐/null‐cell phenotype: report of two cases

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 6, 2015-06 ,pp. : 1637-1641

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30‐positive lymphoproliferative disease

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 3, 2015-03 ,pp. : 784-788

John Wiley & Sons Inc

Access to resources Recommend Favorite